Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Oberon Capital
Deal Size : $2.6 million
Deal Type : Financing
MGC Pharma Launches Share Purchase Plan
Details :
Product Name : CannEpil
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 08, 2023
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Oberon Capital
Deal Size : $2.6 million
Deal Type : Financing
Lead Product(s) : Curcumin,Boswellia Serata
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : CimetrA
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 09, 2021
Lead Product(s) : Curcumin,Boswellia Serata
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Artemisinin,Boswellia Serata
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Malta Enerprises
Deal Size : $3.7 million
Deal Type : Funding
MGC Pharmaceuticals Receives Cash Grant to Help Establish ArtemiCTM Productioninn Malta
Details :
Product Name : ArtemiC
Product Type : Other Small Molecule
Upfront Cash : $3.7 million
December 22, 2020
Lead Product(s) : Artemisinin,Boswellia Serata
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Malta Enerprises
Deal Size : $3.7 million
Deal Type : Funding
Lead Product(s) : Artemisinin,Curcumin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : ArtemiC
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2020
Lead Product(s) : Artemisinin,Curcumin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Artemisinin,Curcumin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MGC Pharmaceuticals Provides ArtemiCTM Phase II Clinical Trial Results Update
Details :
Product Name : ArtemiC
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2020
Lead Product(s) : Artemisinin,Curcumin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ArtemiC
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MGC Starts Phase II Study of ArtemiC to Treat Covid-19
Details :
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 05, 2020
Lead Product(s) : ArtemiC
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable